Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Qualigen, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system; ALAN, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; AS1411 for treating viral-based infectious diseases; RAS-F3, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient`s blood. Qualigen, Inc. was founded in 1996 and is based in Carlsbad, California.
Website: qualigeninc.com



Growth: Good revenue growth rate >200%, there is acceleration compared to average historical growth rates 73.6%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is negative, -129.4%. On average the margin is decreasing steadily. Gross margin is low, -0.1%. In the last quarter the company beat the estimated EPS. The company was ahead of estimated EPS in 75% of quarters (showing a gain of +$0.25 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -402.5% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 3 162.2% higher than minimum and 46.6% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 3.8x by EV / Sales multiple , the company can be >100% undervalued

Key Financials (Download financials)

Ticker: QLGN
Share price, USD:  (0.0%)3.21
year average price 3.22  


year start price 3.38 2025-02-13

min close price 1.67 2025-08-13

max close price 6.01 2025-10-01

current price 3.21 2026-02-12
Common stocks: 387 000

Dividend Yield:  0.0%
EV / Sales: 0.1x
Margin (EBITDA LTM / Revenue): -129.4%
Fundamental value created in LTM:
Market Cap ($m): 1
Net Debt ($m): 1
EV (Enterprise Value): 2
Price to Book: 0.0x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2025-10-27globenewswire.com

Qualigen Therapeutics to Rebrand as AIxCrypto After Stockholder Meeting on November 12, with Three Core Goals for 2025

2025-10-24benzinga.com

Qualigen Therapeutics (QLGN) Stock Soars 62% After-Hours On Partnership With BitGo To Build Multi-Asset Crypto Treasury

2025-09-30globenewswire.com

Faraday Future Announces Closing of Strategic $41 Million Investment in Qualigen Therapeutics (NASDAQ: QLGN) to Accelerate its Dual-Flywheel & Dual-Bridge Eco Strategy

2025-09-21globenewswire.com

Faraday Future Announced a Total Strategic Investment of $41 million in Qualigen Therapeutics, Inc. (NASDAQ: QLGN) During its Annual 919 Event, for its Crypto Business Focusing on Three Growth Engines

2025-09-19globenewswire.com

Faraday Future Announces Strategic $41 Million Investment in Qualigen Therapeutics, Inc. (NASDAQ: QLGN) for Crypto Business Through PIPE Transaction

2025-09-19globenewswire.com

Faraday Future Announces Strategic $41 Million Investment in Qualigen Therapeutics, Inc. (NASDAQ: QLGN) f for Crypto Business Through PIPE Transaction

2024-11-25globenewswire.com

Univest Securities, LLC Announces Successful Closing of $5.1 Million Private Placement for Qualigen Therapeutics, Inc. (NASDAQ: QLGN)

2024-11-01globenewswire.com

Shares Expected to Begin Trading on Split-Adjusted Basis on November 5, 2024

2024-09-26globenewswire.com

Qualigen Therapeutics, Inc. Announces management changes.

2024-09-06globenewswire.com

Univest Securities, LLC Announces Closing of $3.46 Million Registered Direct Offering for its Client Qualigen Therapeutics, Inc. (NASDAQ: QLGN)
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2021-12-31 2020-12-31
symbol QLGN QLGN QLGN QLGN QLGN QLGN QLGN QLGN QLGN QLGN QLGN QLGN QLGN QLGN QLGN
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-14 2025-08-14 2024-11-14 2024-08-14 2024-03-31 2023-11-14 2023-08-14 2023-05-15 2022-11-14 2022-08-15
acceptedDate 2025-11-14 17:16:14 2025-08-14 17:29:11 2025-06-30 17:28:36 2024-11-14 16:25:34 2024-08-14 16:06:05 2024-03-29 20:00:00 2023-12-29 19:00:00 2023-11-14 16:54:20 2023-08-14 16:16:09 2023-05-15 16:06:27 2023-05-02 16:26:02 2022-11-14 16:53:47 2022-08-15 16:17:49 2022-04-29 16:52:46 2020-12-30 19:00:00
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 Q2 FY FY
revenue 0 0 0 0 0 0 5M 8M 2M 2M 5M 1M 1M 6M 4M
costOfRevenue 0 0 0 0 754 287 364 385 5M 6M 1M 1M 4M 1M 1M 4M 7M
grossProfit 0 0 0 0 -754 287 -364 385 -4495 2M 610 489 342 342 680 801 163 036 330 857 1M -3M
grossProfitRatio 0 0 0 0 0 0.296 0.375 0.213 0.113 0.231
researchAndDevelopmentExpenses 105 576 17 815 1M 123 429 754 287 364 385 5M 1M 1M 2M 7M 2M 2M 12M 4M
generalAndAdministrativeExpenses 0 0 4M 1M 986 484 1M 6M 1M 3M 2M 11M 3M 3M 12M 8M
sellingAndMarketingExpenses 0 0 0 0 0 -9737 -4495 0 169 223 199 114 950 420 239 865 305 103 542 594 400 165
sellingGeneralAndAdministrativeExpenses 1M 2M 4M 1M 986 484 1M 6M 1M 3M 2M 12M 3M 3M 12M 8M
otherExpenses 0 0 360 000 0 0 -356 660 -5M 33 454 5680 4881 1125 0 0 5446 -2M
operatingExpenses 1M 2M 6M 1M 2M 1M 6M 3M 4M 4M 19M 5M 4M 24M 10M
costAndExpenses 1M 2M 6M 1M 2M 1M 11M 3M 5M 5M 23M 6M 6M 28M 17M
interestIncome 193 819 142 477 128 795 48 082 0 0 0 0 760 416 0 0 4631 4824 42 693 138 796
interestExpense 455 941 106 052 908 943 408 359 263 560 136 556 2M 367 257 377 416 544 236 34 397 4631 -19 248 0 0
depreciationAndAmortization 0 0 0 -119 318 1124 1124 4495 -239 090 122 787 121 184 12 165 -231 751 77 017 322 059 138 652
ebitda -2M -2M -5M -1M -1M -1M -11M -3M -4M -4M -14M -5M -4M -22M -11M
ebitdaratio 0 0 0 0 0 -0.334 -2.339 -2.222 -3.202 -2.841
operatingIncome -1M -2M -6M -1M -2M -1M -11M -3M -4M -4M -18M -4M -4M -23M -13M
operatingIncomeRatio 0 0 0 0 0 -0.35 -2.183 -2.298 -3.041 -2.895
totalOtherIncomeExpensesNet -608 134 -1670 -391 137 -527 677 263 001 -618 955 -1M -89 405 382 672 -578 269 872 806 327 070 19 248 5M -8M
incomeBeforeTax -2M -2M -6M -2M -1M -2M -12M -3M -4M -4M -21M -4M -4M -18M -20M
incomeBeforeTaxRatio 0 0 0 0 0 -0.407 -2.179 -2.657 -2.814 -2.881
incomeTaxExpense 0 0 6334 -2198 -1212 1786 -4793 421 512 -38 182 -163 777 -265 074 -230 767 5438 5427 -619
netIncome -2M -2M -6M -2M -2M -2M -13M -4M -3M -4M -21M -4M -4M -18M -20M
netIncomeRatio 0 0 0 0 0 -0.46 -2.129 -2.556 -2.654 -2.885
eps -1.73 -1 -17.28 -4.71 -0.21 -0.34 -2.46 -0.72 -0.69 -0.83 -5.48 -0.97 -1.13 -6.1 -7.98
epsdiluted -1.73 -1 -4.7 -0.21 -0.34 -0.72 -0.69 -0.83 -0.97 -1.13
weightedAverageShsOut 2M 2M 361 587 387 000 8M 6M 5M 5M 5M 5M 4M 4M 4M 3M 3M
weightedAverageShsOutDil 2M 2M 361 587 387 878 8M 6M 5M 5M 5M 5M 4M 4M 4M 3M 3M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-06-30 2023-12-31 2023-05-02 2022-04-29 2020-12-31
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome -780 148 -2M -34 397 42 693 -138 796
ebit -5M -11M -14M -23M -11M
nonOperatingIncomeExcludingInterest -517 810 0 -907 203 0 -1M
netIncomeFromContinuingOperations -6M -12M -14M -18M -20M
netIncomeFromDiscontinuedOperations 0 -683 008 -5M 0 0
otherAdjustmentsToNetIncome 0 -602 232 -2M 0 0
netIncomeDeductions 0 -602 232 0 0 0
bottomLineNetIncome -6M -12M -19M -18M -20M
epsDiluted -17.28 -2.46 -5.48 -6.1 -7.89

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2021-12-31 2020-12-31
symbol QLGN QLGN QLGN QLGN QLGN QLGN QLGN QLGN QLGN QLGN QLGN QLGN QLGN QLGN QLGN
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-14 2025-08-14 2024-11-14 2024-08-14 2024-03-31 2023-11-14 2023-08-14 2023-05-15 2022-11-14 2022-08-15
acceptedDate 2025-11-14 17:16:14 2025-08-14 17:29:11 2025-06-30 17:28:36 2024-11-14 16:25:34 2024-08-14 16:06:05 2024-03-29 20:00:00 2023-12-29 19:00:00 2023-11-14 16:54:20 2023-08-14 16:16:09 2023-05-15 16:06:27 2023-05-02 16:26:02 2022-11-14 16:53:47 2022-08-15 16:17:49 2022-04-29 16:52:46 2020-12-30 19:00:00
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 Q2 FY FY
cashAndCashEquivalents 39M 331 601 1M 388 152 118 685 543 217 401 803 2M 1M 4M 3M 7M 10M 18M 24M
shortTermInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
cashAndShortTermInvestments 39M 331 601 1M 388 152 118 685 543 217 401 803 2M 1M 4M 3M 7M 10M 18M 24M
netReceivables 0 3M 2M 1M 0 0 0 235 402 679 380 411 104 538 587 603 291 719 883 822 351 615 757
inventory 0 0 0 0 0 0 0 -235 402 2M 1M 2M 1M 1M 1M 953 458
otherCurrentAssets 5M 316 576 31 200 626 760 415 725 459 994 0 1M 11 636 12 161 4M 2M 2M 3577 0
totalCurrentAssets 43M 4M 5M 2M 534 410 1M 1M 3M 5M 8M 11M 10M 14M 21M 28M
propertyPlantEquipmentNet 0 0 0 0 0 0 0 0 2M 2M 26 242 2M 2M 2M 696 065
goodwill 0 0 0 0 0 0 0 0 625 602 625 602 625 602 5M 5M 0 0
intangibleAssets 0 0 0 0 0 0 0 0 6M 6M 6M 6M 6M 171 190 187 694
goodwillAndIntangibleAssets 0 0 0 0 0 0 0 0 6M 6M 6M 11M 11M 171 190 187 694
longTermInvestments 0 0 0 0 0 0 0 0 5434 0 0 0 0 0 0
taxAssets 0 0 0 0 0 0 0 0 -5434 0 0 0 0 0 0
otherNonCurrentAssets 2000 2000 2000 0 0 0 866 481 866 481 23 768 23 920 2M 23 958 24 052 18 334 18 334
totalNonCurrentAssets 2000 2000 2000 0 0 0 866 481 866 481 8M 8M 8M 13M 13M 2M 902 093
otherAssets 0 0 0 0 0 0 0 0 0 -1 0 0 0 -1 0
totalAssets 43M 4M 5M 2M 534 410 1M 2M 4M 13M 16M 19M 23M 26M 23M 29M
accountPayables 1M 1M 2M 2M 2M 2M 2M 2M 2M 899 948 619 568 596 039 918 327 886 224 500 768
shortTermDebt 3M 4M 0 1M 2M 1M 1M 832 100 2M 2M 60 197 1M 1M 0 131 766
taxPayables 0 0 0 0 0 0 0 0 37 328 27 618 32 194 27 041 24 823 17 710 0
deferredRevenue 0 0 0 0 0 0 0 1M 94 474 112 902 116 161 102 640 109 833 135 063 0
otherCurrentLiabilities 404 219 593 609 269 175 1M 1M 2M 63 450 2M 5M 5M 7M 3M 4M 2M 9M
totalCurrentLiabilities 5M 6M 2M 4M 5M 5M 4M 6M 8M 8M 9M 5M 6M 5M 10M
longTermDebt 0 0 0 0 0 0 0 0 1M 1M 0 1M 1M 0 6973
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 28 648 40 712 49 056 60 521 70 814 92 928 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 150 369 192 587 357 757 736 000 736 000 0 0
otherNonCurrentLiabilities -0 0 0 0 0 0 0 0 0 1 0 323 667 87 104 0 158 271
totalNonCurrentLiabilities -0 0 0 0 0 0 0 0 1M 1M 2M 2M 2M 2M 402 070
otherLiabilities 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 0 0 0 0 0 0 0 0 1M 1M 2M 2M 2M 2M 491 565
totalLiabilities 5M 6M 2M 4M 5M 5M 4M 6M 10M 10M 10M 7M 8M 6M 11M
preferredStock 36M 3M 6M 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 67 734 66 213 65 314 65 314 47 514 44 400 43 262 42 952 42 952 42 952 42 110 42 110 38 795 35 290 27 296
retainedEarnings -129M -127M -123M -122M -120M -119M -117M -114M -111M -107M -103M -97M -93M -85M -67M
accumulatedOtherComprehensiveIncomeLoss 0 0 0 0 0 0 0 0 131 891 170 444 50 721 154 063 65 540 0 0
othertotalStockholdersEquity 132M 123M 120M 116M 115M 113M 113M 112M 109M 108M
totalStockholdersEquity 39M -2M 3M -2M -4M -4M -2M -2M 2M 5M 7M 12M 14M 17M 18M
totalEquity 39M -2M 3M -2M -4M -4M -2M -2M 3M 6M 9M 12M 14M 17M 18M
totalLiabilitiesAndStockholdersEquity 43M 4M 2M 534 410 1M 4M 13M 16M 23M 26M
minorityInterest 0 0 0 0 0 0 0 0 1M 1M 2M 0 0 0 0
totalLiabilitiesAndTotalEquity 43M 4M 5M 2M 534 410 1M 2M 4M 13M 16M 19M 23M 26M 23M 29M
totalInvestments 0 0 0 0 0 0 0 0 5434 0 0 0 0 0 0
totalDebt 3M 4M 0 1M 2M 1M 1M 832 100 3M 3M 2M 3M 3M 2M 630 304
netDebt -36M 3M -1M 1M 2M 479 652 897 413 -1M 2M -1M -1M -4M -7M -16M -23M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-06-30 2023-12-31 2023-05-02 2022-04-29 2020-12-31
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 2M 0 538 587 822 351 615 757
otherReceivables 0 0 0 0 0
prepaids 1M 764 964 1M 1M 3M
totalPayables 2M 2M 619 568 903 934 500 768
otherPayables 0 0 0 17 710 0
accruedExpenses 170 243 551 156 794 559 2M 583 927
capitalLeaseObligationsCurrent 0 0 395 078 134 091 254 739
capitalLeaseObligationsNonCurrent 0 0 1M 2M 236 826
treasuryStock 0 0 0 0 0
additionalPaidInCapital 120M 115M 111M 101M 85M
otherTotalStockholdersEquity 0 0 0 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2021-12-31 2020-12-31
symbol QLGN QLGN QLGN QLGN QLGN QLGN QLGN QLGN QLGN QLGN QLGN QLGN QLGN QLGN QLGN
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-14 2025-08-14 2024-11-14 2024-08-14 2024-03-31 2023-11-14 2023-08-14 2023-05-15 2022-11-14 2022-08-15
acceptedDate 2025-11-14 17:16:14 2025-08-14 17:29:11 2025-06-30 17:28:36 2024-11-14 16:25:34 2024-08-14 16:06:05 2024-03-29 20:00:00 2023-12-29 19:00:00 2023-11-14 16:54:20 2023-08-14 16:16:09 2023-05-15 16:06:27 2023-05-02 16:26:02 2022-11-14 16:53:47 2022-08-15 16:17:49 2022-04-29 16:52:46 2020-12-30 19:00:00
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 Q2 FY FY
netIncome -2M -2M -6M -2M -1M -2M -12M -2M -4M -4M -12M -4M -4M -18M -20M
depreciationAndAmortization 0 0 0 0 0 0 4495 -239 090 122 787 116 303 12 165 89 549 91 817 338 277 314 203
deferredIncomeTax 0 0 0 0 0 0 0 -150 369 -410 664 -165 170 0 0 0 0 0
stockBasedCompensation 0 0 128 059 27 208 33 086 58 651 1M 122 696 653 919 252 226 0 1M 1M 5M 3M
changeInWorkingCapital -486 639 292 594 -783 584 -700 791 275 343 602 845 1M 141 376 -40 857 654 975 -642 866 -495 381 -1M 2M -2M
accountsReceivables 0 0 0 0 0 0 0 0 -255 259 246 645 417 708 -46 504 -65 941 41 250 545 583
inventory 0 0 0 0 0 0 0 0 -108 769 71 379 0 -200 133 110 978 111 422 -326 067
accountsPayables -122 387 -126 124 -445 141 -215 449 52 561 -421 649 2M 52 516 856 616 43 137 -43 440 -322 454 -83 243 385 455 0
otherWorkingCapital -364 252 418 718 -338 443 -485 342 222 782 1M -491 842 88 860 -533 445 293 814 -1M 73 710 -1M 2M -2M
otherNonCashItems 382 977 294 711 687 213 667 780 -306 403 1M -43 861 3M 254 181 614 822 -1M -129 813 -22 445 -5M 10M
netCashProvidedByOperatingActivities -2M -1M -6M -2M -1M -783 586 -10M 929 739 -3M -3M -13M -3M -4M -15M -10M
investmentsInPropertyPlantAndEquipment 0 0 0 0 0 0 0 246 418 -48 409 -198 009 0 -11 260 -13 858 -134 471 -210 193
acquisitionsNet 0 0 0 0 0 0 0 0 0 0 0 0 135 354 0 0
purchasesOfInvestments 0 -1M 0 0 0 0 0 0 0 0 0 0 0 0 0
salesMaturitiesOfInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherInvestingActivites -291 000 0 -1M 350 000 0 4M 0 0 0 0
netCashUsedForInvestingActivites -291 000 -1M -1M 350 000 0 4M -48 409 -198 009 -11 260 121 496
debtRepayment -1M 3M 0 1 000 000 -475 000 -440 000 0 0 0 0
commonStockIssued 42M 3M -150 000 150 000 0 0 0 0 0 2M
commonStockRepurchased 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
dividendsPaid 0 -1586 0 0 0 0 0 0 0 0
otherFinancingActivites 0 -3M 3M 150 000 0 0 0 0 3314 -2M
netCashUsedProvidedByFinancingActivities 41M 3M 3M 1M 475 000 -440 000 -1 1 3314 1
effectOfForexChangesOnCash 1 0 0 0 0 0 0 -115 803 -44 517 160 320 -4M 61 751 -34 228 0 -24M
netChangeInCash 38M 301 391 772 805 269 467 25 468 141 414 -7M 726 756 -3M -3M -14M -3M -4M -6M 27 998
cashAtEndOfPeriod 39M 331 601 1M 388 152 118 685 543 217 401 803 2M 1M 4M 3M 7M 10M 18M 153 121
cashAtBeginningOfPeriod 331 601 30 210 401 803 118 685 93 217 401 803 7M 1M 4M 7M 18M 10M 14M 24M 125 123
operatingCashFlow -2M -1M -6M -2M -1M -783 586 -10M 929 739 -3M -3M -13M -3M -4M -15M -10M
capitalExpenditure 0 0 0 -2 2 0 0 246 418 -48 409 -198 009 -319 119 -11 260 -13 858 -141 364 -210 193
freeCashFlow -2M -1M -6M -2M -1M -783 586 -10M 1M -3M -3M -14M -3M -4M -15M -10M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-06-30 2023-12-31 2023-05-02 2022-04-29 2020-12-31
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities -2M 4M -183 763 -6893 49 638
netCashProvidedByInvestingActivities -2M 4M -183 763 -141 364 -160 555
netDebtIssuance 1M -550 000 3M -138 739 165 144
longTermNetDebtIssuance 0 0 0 -138 739 165 144
shortTermNetDebtIssuance 1M -550 000 3M 0 0
netStockIssuance 8M 0 7173 9M 0
netCommonStockIssuance 3M 0 7173 9M 0
commonStockIssuance 3M 0 7173 9M 0
netPreferredStockIssuance 5M 0 0 0 0
netDividendsPaid -87 604 0 0 0 0
commonDividendsPaid -87 604 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities 4563 0 -505 -247 453 34M
netCashProvidedByFinancingActivities 9M -550 000 3M 8M 34M
incomeTaxesPaid 5522 5571 0 5133 0
interestPaid 92 838 0 0 1233 0

Earning call transcript

SEC forms

Show financial reports only

SEC form 8
2026-01-06 18:32 ET
Qualigen Therapeutics published news for 2025 q4
SEC form 8
2026-01-06 18:32 ET
Qualigen Therapeutics published news for 2025 q4
SEC form 8
2025-12-16 01:03 ET
Qualigen Therapeutics published news for 2025 q3
SEC form 8
2025-12-16 01:03 ET
Qualigen Therapeutics published news for 2025 q3
SEC form 8
2025-11-21 21:23 ET
Qualigen Therapeutics published news for 2025 q3
SEC form 8
2025-11-21 21:23 ET
Qualigen Therapeutics published news for 2025 q3
SEC form 10
2025-11-14 17:16 ET
Qualigen Therapeutics reported for 2025 q3
SEC form 10
2025-08-14 21:29 ET
Qualigen Therapeutics reported for 2025 q2
SEC form 10
2025-07-21 21:27 ET
Qualigen Therapeutics reported for 2025 q1
SEC form 10
2025-07-21 00:00 ET
Qualigen Therapeutics reported for 2025 q1
SEC form 8
2025-07-16 13:28 ET
Qualigen Therapeutics published news for 2025 q2
SEC form 8
2025-07-16 13:28 ET
Qualigen Therapeutics published news for 2025 q2
SEC form 10
2025-06-30 21:28 ET
Qualigen Therapeutics reported for 2024 q4
SEC form 10
2025-06-30 00:00 ET
Qualigen Therapeutics reported for 2024 q4
SEC form 8
2025-01-28 21:10 ET
Qualigen Therapeutics published news for 2024 q4
SEC form 8
2025-01-28 21:10 ET
Qualigen Therapeutics published news for 2024 q4
SEC form 10
2024-11-14 16:25 ET
Qualigen Therapeutics reported for 2024 q3
SEC form 10
2024-11-14 00:00 ET
Qualigen Therapeutics reported for 2024 q3
SEC form 10
2024-08-14 00:00 ET
Qualigen Therapeutics reported for 2024 q2
SEC form 10
2024-07-02 00:00 ET
Qualigen Therapeutics reported for 2024 q1
SEC form 10
2024-04-08 00:00 ET
Qualigen Therapeutics reported for 2023 q4
SEC form 10
2023-11-14 00:00 ET
Qualigen Therapeutics reported for 2023 q3
SEC form 8
2023-08-15 00:00 ET
Qualigen Therapeutics reported for 2023 q2
SEC form 10
2023-08-14 00:00 ET
Qualigen Therapeutics reported for 2023 q2
SEC form 10
2023-05-15 00:00 ET
Qualigen Therapeutics reported for 2023 q1
SEC form 10
2023-05-02 00:00 ET
Qualigen Therapeutics reported for 2022 q4
SEC form 6
2023-03-31 16:05 ET
Qualigen Therapeutics published news for 2022 q4
SEC form 6
2023-02-13 09:30 ET
Qualigen Therapeutics published news for 2022 q4
SEC form 6
2023-01-20 16:30 ET
Qualigen Therapeutics published news for 2022 q4
SEC form 6
2023-01-10 16:15 ET
Qualigen Therapeutics published news for 2022 q4
SEC form 6
2022-12-22 16:15 ET
Qualigen Therapeutics published news for 2022 q3
SEC form 6
2022-12-12 09:01 ET
Qualigen Therapeutics published news for 2022 q3
SEC form 6
2022-11-22 09:10 ET
Qualigen Therapeutics published news for 2022 q3
SEC form 10
2022-11-14 16:53 ET
Qualigen Therapeutics reported for 2022 q3
SEC form 10
2022-11-14 00:00 ET
Qualigen Therapeutics reported for 2022 q3
SEC form 6
2022-10-28 17:03 ET
Qualigen Therapeutics published news for 2022 q3
SEC form 6
2022-10-26 09:00 ET
Qualigen Therapeutics published news for 2022 q3
SEC form 6
2022-09-02 07:00 ET
Qualigen Therapeutics published news for 2022 q2
SEC form 6
2022-08-26 16:15 ET
Qualigen Therapeutics published news for 2022 q2
SEC form 6
2022-08-16 06:20 ET
Qualigen Therapeutics published news for 2022 q2
SEC form 8
2022-08-16 00:00 ET
Qualigen Therapeutics reported for 2022 q2
SEC form 10
2022-08-15 16:17 ET
Qualigen Therapeutics reported for 2022 q2
SEC form 10
2022-08-15 00:00 ET
Qualigen Therapeutics reported for 2022 q2
SEC form 6
2022-08-04 16:17 ET
Qualigen Therapeutics published news for 2022 q2
SEC form 6
2022-08-04 16:16 ET
Qualigen Therapeutics published news for 2022 q2
SEC form 6
2022-08-04 16:16 ET
Qualigen Therapeutics published news for 2022 q2
SEC form 6
2022-08-04 16:16 ET
Qualigen Therapeutics published news for 2022 q2
SEC form 6
2022-08-04 16:16 ET
Qualigen Therapeutics published news for 2022 q2
SEC form 6
2022-08-04 16:16 ET
Qualigen Therapeutics published news for 2022 q2
SEC form 6
2022-08-04 16:16 ET
Qualigen Therapeutics published news for 2022 q2
SEC form 6
2022-08-04 16:16 ET
Qualigen Therapeutics published news for 2022 q2
SEC form 6
2022-08-04 16:16 ET
Qualigen Therapeutics published news for 2022 q2
SEC form 6
2022-07-13 06:15 ET
Qualigen Therapeutics published news for 2022 q2
SEC form 6
2022-07-01 16:15 ET
Qualigen Therapeutics published news for 2022 q2
SEC form 6
2022-06-22 16:55 ET
Qualigen Therapeutics published news for 2022 q1
SEC form 6
2022-06-15 16:05 ET
Qualigen Therapeutics published news for 2022 q1
SEC form 6
2022-06-02 09:10 ET
Qualigen Therapeutics published news for 2022 q1
SEC form 10
2022-05-13 06:10 ET
Qualigen Therapeutics reported for 2022 q1
SEC form 6
2022-05-13 06:05 ET
Qualigen Therapeutics published news for 2022 q1
SEC form 8
2022-05-13 00:00 ET
Qualigen Therapeutics reported for 2022 q1
SEC form 10
2022-05-13 00:00 ET
Qualigen Therapeutics reported for 2022 q1
SEC form 6
2022-05-04 16:06 ET
Qualigen Therapeutics published news for 2022 q1
SEC form 6
2022-04-29 16:52 ET
Qualigen Therapeutics published news for 2022 q1
SEC form 10
2022-03-31 16:06 ET
Qualigen Therapeutics published news for 2021 q4
SEC form 10
2022-03-31 00:00 ET
Qualigen Therapeutics published news for 2021 q4
SEC form 6
2022-03-04 17:18 ET
Qualigen Therapeutics published news for 2021 q4
SEC form 6
2022-01-18 09:30 ET
Qualigen Therapeutics published news for 2021 q4
SEC form 6
2021-12-17 06:15 ET
Qualigen Therapeutics published news for 2021 q3
SEC form 6
2021-12-10 13:09 ET
Qualigen Therapeutics published news for 2021 q3
SEC form 6
2021-12-09 17:25 ET
Qualigen Therapeutics published news for 2021 q3
SEC form 6
2021-12-01 15:39 ET
Qualigen Therapeutics published news for 2021 q3
SEC form 10
2021-11-15 09:00 ET
Qualigen Therapeutics published news for 2021 q3
SEC form 10
2021-11-15 00:00 ET
Qualigen Therapeutics published news for 2021 q3
SEC form 10
2021-08-16 16:16 ET
Qualigen Therapeutics published news for 2021 q2
SEC form 10
2021-08-16 00:00 ET
Qualigen Therapeutics published news for 2021 q2
SEC form 6
2021-08-13 16:05 ET
Qualigen Therapeutics published news for 2021 q2
SEC form 6
2021-05-17 17:21 ET
Qualigen Therapeutics published news for 2021 q1
SEC form 6
2021-05-17 16:23 ET
Qualigen Therapeutics published news for 2021 q1
SEC form 10
2021-05-14 13:01 ET
Qualigen Therapeutics published news for 2021 q1
SEC form 10
2021-05-14 00:00 ET
Qualigen Therapeutics published news for 2021 q1
SEC form 6
2021-04-29 15:16 ET
Qualigen Therapeutics published news for 2021 q1
SEC form 6
2021-04-09 16:10 ET
Qualigen Therapeutics published news for 2021 q1
SEC form 6
2021-03-31 16:33 ET
Qualigen Therapeutics published news for 2020 q4
SEC form 6
2021-03-05 09:15 ET
Qualigen Therapeutics published news for 2020 q4
SEC form 6
2021-01-06 16:18 ET
Qualigen Therapeutics published news for 2020 q4
SEC form 6
2020-12-18 15:54 ET
Qualigen Therapeutics published news for 2020 q3
SEC form 6
2020-12-08 09:30 ET
Qualigen Therapeutics published news for 2020 q3
SEC form 6
2020-12-07 16:32 ET
Qualigen Therapeutics published news for 2020 q3
SEC form 10
2020-11-12 17:14 ET
Qualigen Therapeutics published news for 2020 q3
SEC form 6
2020-11-03 16:15 ET
Qualigen Therapeutics published news for 2020 q3
SEC form 6
2020-10-09 16:15 ET
Qualigen Therapeutics published news for 2020 q3
SEC form 6
2020-10-02 16:43 ET
Qualigen Therapeutics published news for 2020 q3